Study guide
5.6 Packaging of Dispensed Drugs
Pennsylvania MPJE Pharmacy Jurisprudence Exam
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 About the PA MPJE Exam 1.2 How to Use This Study Guide
2 Federal Pharmacy Law Foundations
2.1 Controlled Substances Act & DEA Scheduling 2.2 DEA Forms, Registration & Security 2.3 Federal Food, Drug, and Cosmetic Act 2.4 HIPAA & Patient Privacy 2.5 OBRA '90, Medicare/Medicaid & DUR 2.6 DSCSA & Drug Supply Chain Integrity
3 Area 1: Licensure & Personnel (22%)
3.1 Pharmacist Licensure & the PA Board of Pharmacy 3.2 Pharmacist-in-Charge Responsibilities 3.3 Pharmacy Interns & Practical Experience 3.4 Pharmacy Technicians & Trainees (PA Registration) 3.5 License Renewal, CE & Discipline 3.6 Impaired-Pharmacist Programs & Mandatory Reporting
4 Area 2: Pharmacist Practice (33%)
4.1 Prescription Requirements & Practitioner Authority 4.2 Controlled Substance Prescribing (Federal + PA) 4.3 Refills & Authority Limitations 4.4 Drug Administration & Collaborative Practice Agreements 4.5 Patient Counseling & Documentation 4.6 Returning & Reusing Drugs 4.7 Immunizations, Naloxone & Public Health 4.8 Patient Confidentiality & Pharmacy Records
5 Area 3: Dispensing Requirements (24%)
5.1 Legitimate Medical Purpose Verification 5.2 Prescription Transfers Between Pharmacies 5.3 Prospective DUR & the PA PDMP (ABC-MAP) 5.4 Refill Exceptions & Emergency Dispensing 5.5 Labeling of Dispensed Drugs 5.6 Packaging of Dispensed Drugs 5.7 Drugs & Conditions Prohibiting Dispensing 5.8 OTC, Behind-the-Counter & Hazardous Drugs
6 Area 4: Pharmacy Operations (21%)
6.1 Ordering, Acquisition & Distribution Records 6.2 Recordkeeping, Storage & Handling 6.3 Controlled Substance Inventories 6.4 Delivery of Drugs 6.5 Product Selection & Generic Substitution 6.6 Compounding: Sterile, Nonsterile & Hazardous 6.7 Central Fill & Centralized Prescription Processing 6.8 Pharmacy Permits, Inspections & Discipline
7 Test-Day Strategy & Final Review
7.1 When PA Law Is Stricter Than Federal Law 7.2 Test-Day Strategy & Common Traps
5.6 Packaging of Dispensed Drugs
Key Takeaways Explain This Topic AI
USP General Chapter <659> defines container classes (tight, well-closed, hermetic, single-unit, multiple-unit); downgrading protection makes a product misbranded.
Default nonsterile solid BUD under USP <659> is 1 year or the manufacturer's expiration, whichever is earlier; reconstituted products follow the manufacturer's reconstitution instructions.
Pharmacist-assigned BUDs may never exceed the manufacturer's expiration date of the original product.
Single-dose vials (SDVs) lack antimicrobial preservative and are intended for one patient, one procedure; multi-dose vials (MDVs) contain preservative and are typically assigned a 28-day BUD after first puncture under USP <797>.
PA pharmacies compounding sterile products must follow USP <797> (current revision effective Nov 2023).
Last updated: July 2026
Packaging as an MPJE Topic
Packaging is more than the sticker — it is the physical container that protects the drug, the legal unit that determines beyond-use dating, and the safety mechanism (child resistance) that prevents pediatric poisoning. The MPJE tests packaging in three layers: (1) federal standards under the FDCA and PPPA, (2) USP General Chapter <659> Packaging and Storage Requirements , and (3) PA's specific rules on repackaging, unit-dose, and beyond-use dating in 49 Pa. Code § 27.18 .
Container Types Under USP <659>
USP <659> defines container classes based on how they protect the contents:
- Container class Definition Typical use
- Tight container Protects from moisture, vapor, and loss of solvent Most oral solids, capsules
Well-closed container Protects from foreign solids and loss of contents Coated tablets where moisture is not a concern
- Hermetic container Impervious to air and gases; absolute barrier Sterile products, injectables, biologics
- Single-unit container Holds one dose of one drug Unit-dose blister
- Multiple-unit container Holds more than one dose Stock bottle, dispensed vial
The pharmacist-manager (§ 27.11) must select packaging that preserves the drug's labeled storage conditions; repackaging into a container that downgrades protection (e.g., a tight drug moved to a well-closed container) is misbranding.
Repackaging Rules
Under PA and federal rules, a pharmacy may repackage a manufacturer's stock into smaller dispensing units without a separate FDA registration only if (1) the repackage holds a valid state pharmacy permit, (2) the repackaged product is labeled with all § 27.18(d) elements plus the original manufacturer's lot number and expiration, (3) records identify the source lot for recall traceability, and (4) the beyond-use date assigned follows USP <659> (generally 1 year or manufacturer expiration, whichever is shorter, for solids in tight containers). A repackager operating at scale outside traditional pharmacy practice is a 503B outsourcing facility requiring FDA registration under FDCA § 503B.
Unit-Dose and Limited-Quantity Packaging
Unit-dose packaging means one dose per individually labeled unit. It is standard in institutional (hospital and long-term-care) settings because it reduces administration errors, supports barcode medication administration, and limits cross-contamination. PA requires that LTC and institutional pharmacies operating under a pharmacy services agreement use unit-dose where feasible. Limited-quantity packaging (e.g., a 10-day course dispensed in unit-of-use blisters) follows the same labeling requirements as bulk dispensing.
Beyond-Use Date vs Expiration Date
Term Definition Authority
Expiration date Manufacturer's stability date; shelf life of unopened, intact product 21 CFR § 201.18; USP <659>
Beyond-use date (BUD) Patient-use date assigned at dispensing; reflects opened/repackaged conditions USP <795>, <797>, <659>
Default nonsterile BUDs per USP <659>: solid orals in tight containers — 1 year or manufacturer expiration, whichever is earlier; water-containing oral liquids — 35 days refrigerated or per stability data; reconstituted powders — per manufacturer label. Pharmacist-assigned BUDs may never exceed the manufacturer's expiration date of the original product. A label that prints the original expiration as the BUD for a reconstituted suspension is incorrect — the suspension's BUD is governed by the reconstitution instructions (e.g., 14 days refrigerated for amoxicillin oral suspension).
Child-Resistant vs Senior-Friendly
PPPA-compliant packaging is child-resistant (difficult for children under 5 to open) and senior-friendly (adults can open it). "Senior-friendly" alone is not a substitute — the packaging must meet both performance standards. PA permits a one-time-per-prescription patient request for non-CR packaging; refills require a renewed request unless the patient has a blanket written request on file (49 Pa. Code § 27.18 echoes the PPPA framework). See § 5.5 for the full list of exemptions.
Single-Dose vs Multi-Dose Vials
For sterile products, USP <797> (current revision effective Nov 2023) distinguishes:
Single-dose vial (SDV): lacks antimicrobial preservative; intended for one patient, one procedure. Once entered, it must be used within the manufacturer's labeled time (commonly 6 hours if sterile technique is maintained) and discarded thereafter.
Multi-dose vial (MDV): contains antimicrobial preservative; may be used for multiple patients. The BUD after first puncture per USP <797> is generally 28 days unless the manufacturer specifies otherwise.
PA-licensed pharmacies compounding sterile products must follow USP <797>. Mishandling an SDV as an MDV — entering it more than once and storing it — is a § 27.18 violation and a USP <797> breach.
Common MPJE Traps
Confusing the expiration date with the BUD — the latter is set by the pharmacist at dispensing.
Reusing a single-dose vial across patients — even with preservative, the SDV lacks one.
Repackaging without preserving the source lot — recall traceability breaks, and the product becomes misbranded.
Assigning a 1-year BUD to a reconstituted suspension — only stable solids default to 1 year.
Treating "senior-friendly" as an alternative to CR — it must satisfy both.